Latest filing published 29 Apr 2021 for KalVista Pharmaceuticals, Inc., €72k.
This profile gathers the share dealings of Andreas Maetzel across 2 companies, led by KalVista Pharmaceuticals, Inc. and Critical Therapeutics Inc. Over a trading history stretching from 6 May 2013 to 29 April 2021, the count stands at 15 filings.
Every open-market trade on record is a sale: 7 sales worth €2.0M. Outside the open market, there are 1 share grant and 6 option exercises. 2021 to date brings no purchases and 6 sales.
On 29 April 2021 came the latest disclosure, an option exercise for €72k in KalVista Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations